This CPB has been revised: (i)  to state decitabine (Dacogen) is considered medically necessary for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN), in combination with venetoclax, for relapsed or refractory disease or for systemic disease with palliative intent, (ii) to remove chronic myeloid leukemia as a medically necessary indication, and (iii) to update continued therapy criteria nomenclature. This CPB has been updated to add and reorganize subheaders.